![]() The role of consolidative RT is not clear in the rituximab era due to the lack of phase III trial. The response to chemotherapy is the most important factor affecting both OS and PFS. Estimated 5-year overall survival (OS) and progression-free survival (PFS) rates were, respectively, 84% and 77% for all patients, 100% and 92% for the patients without residual disease after chemotherapy. Complete response was obtained in 27 patients (64.3%), partial response was obtained in 14 patients (33.3%) across all stages. The median follow-up period was 47 months (range, 7–96 months). Ann Arbor clinical stage at diagnosis was as follows: 8 patients (19%) at Stage I, 20 patients (47.6%) at Stage II, 7 patients (16.7%) at Stage III, and 7 patients (16.7%) at Stage IV. The median age at diagnosis was 53 years (range, 18–85 years). The irradiation fields were designed by using involved lymphatic site technique. RT was delivered to a total dose of 30.6–45 Gy with 1.8 Gy daily fractions in 4–5 weeks. All patients received 2–10 cycles of rituximab-containing chemotherapy schedule (mostly CHOP). Material and Methods:įorty-two patients with the diagnosis of mediastinal DLBCL who were treated at the Ege University Hospital between January 2008 and December 2014 were evaluated. The aim of this study is to evaluate the patients treated with consolidative radiotherapy (RT) after rituximab-containing chemotherapy for mediastinal DLBCL regarding treatment outcomes and relapse patterns. Mediastinal DLBCL is a distinct entity with unique clinical, pathologic, and genetic features and accepted as a subtype of DLBCL. Learn more about the stages of non-Hodgkin lymphoma from the National Cancer Institute.The most common subtype of aggressive non-Hodgkin Lymphomas is diffuse large B-cell lymphoma (DLBCL). The disease is metastatic non-Hodgkin lymphoma, not liver cancer. For example, if non-Hodgkin lymphoma spreads to the liver, the cancer cells in the liver are actually non-Hodgkin lymphoma cells. These metastatic cancer cells are the same type of cancer as the primary tumor. When cancer spreads from where it started to another part of the body, it is called metastasis. S (Spleen): This means that the cancer is in the spleen.E (Extranodal): This means that the cancer is outside the lymph system.Here are explanations for the E and S labels of these stages: These are the stages used for non-Hodgkin lymphoma: Cancer spreads in the body in three ways: through tissue, the lymph system, or the blood. Lymph node biopsy: The health care provider removes part or all of a lymph node to look for abnormal cells under a microscope.Ĭancer stages show whether cancer has spread to other parts of the body.Bone marrow biopsy: The health care provider removes a small sample of bone marrow to look for abnormal cells under a microscope.They also look for abnormal amounts of blood cells. Laboratory tests: By testing body tissues, blood, urine, or other substances in the body, your health care team can check to see how the organs are functioning.Your personal health habits, past illnesses, and symptoms help guide the exam. Physical exam and history: A health care provider examines your body for signs of disease.Doctors use these tests to diagnose non-Hodgkin lymphoma:
0 Comments
Leave a Reply. |